Nitric Oxide: A New Biomarker of Doxorubicin Toxicity in Children?

REFERENCES

• Praga C, Beretta G, Vigo PL, Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep. 1979;63:827–834.
   PubMedGoogle Scholar
• Lefrak EA, Pitha J, Rosenheim S, Gattlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32:302–314.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Layard MW, Basa P, Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710–717.
   PubMed Web of Science ®Google Scholar
• Moncada S, Palmer RM, Higgs EA. Nitric oxide physiology, pathophysiology and pharmacology. Pharmacol Rev. 1991;43:109–142.
   PubMed Web of Science ®Google Scholar
• Varin R, Mulder P, Richard V, Exercise improves flow-mediated vasodilatation of skeletal muscle arteries in rats with choronic heart failure: role of nitric oxide, prostanoids, and oxidant stress. Circulation. 1999;99:2951–2957.
   PubMed Web of Science ®Google Scholar
• Kılınc M, Balat A, Cekmen M, Adrenomedullin and nitrite levels in children with dilated cardiomyopathy. Pediatr Cardiol. 2003;24:381–385.
   PubMed Web of Science ®Google Scholar
• Haywood GA, Tsao PS, von der Leyen HE, Expression of inducible nitric oxide synthase in human heart failure. Circulation. 1996;93:1087–1094.
   PubMed Web of Science ®Google Scholar
• Vejlstrup NG, Bouloumie A, Boesgaard S, Inducible nitric oxide synthase (iNOS) in the human heart: expression and localization in congestive heart failure. J Mol Cell Cardiol. 1998;30:1215–1223.
   PubMed Web of Science ®Google Scholar
• Pacher P, Liaudet L, Bai P, Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation. 2003;107:896–904.
   PubMed Web of Science ®Google Scholar
• Elbl L, Hrstkova H, Chaloupka V. The late consequences of anthracycline treatment on left ventricular function after treatment for childhood cancer. Eur J Pediatr. 2003;162:690–696.
   PubMed Web of Science ®Google Scholar
• Bu'lock FA, Mott MG, Oakhill A, Martin RP. Early identification of anthracycline cardiomyopathy: possibilities and implications. Arch Dis Child. 1996;75;416–422.
   PubMed Web of Science ®Google Scholar
• Bories PN, Bories C. Nitrate determination in biological fluids by an enzymatic one-step assay with nitrate reductase. Clin Chem. 1995;41:904–907.
   PubMed Web of Science ®Google Scholar
• Pihkala J, Happonen J, Virtanen K, Cardiopulmonary evaluation of exercise tolerance after chest irradiation and anticancer chemotherapy in children and adolescents. Pediatrics. 1995;95:722–726.
   PubMed Web of Science ®Google Scholar
• Signal PK, Deally CM, Weinberg LE. Subcellular effects of adriamycin in hearth: a concise review. J Mol Cell Cardiol. 1987;19;817–828.
   PubMed Web of Science ®Google Scholar
• Mavinkurve-Groothuis AM, Kapusta L, Nir A, Groot-Loonen J. The role of biomarkers in the early detection of antracycline-induced cardiotoxiciy in children: a review of literature. Pediatr Hematol Oncol. 2008;25:655–664.
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Rifai N, Sallan SE, Predictive value of cardac troponin T in pediatric patients at risk for myocardial injury. Circulation. 1997;96:2641–2648.
   PubMed Web of Science ®Google Scholar
• Fogli S, Nieri P, Breschi MC. The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J. 2004;18:664–675.
   PubMed Web of Science ®Google Scholar
• Adams V, Jiang H, Yu J, Apoptosis in skeletal myocytes of patients with choronic heart failure is associated with exercise intolerance. J Am Coll Cardiol. 1999;33:959–965.
   PubMed Web of Science ®Google Scholar
• Habib FM, Springall DR, Davies GJ, Tumor necrosis factor and inducible nitric oxide syntheses in dilated cardiomyopathy. Lancet. 1998;347:1151–1155.
   Web of Science ®Google Scholar
• Heymes C, Vanderheyden M, Bronzwaer JG, Endomyocardial nitric oxide synthase and left ventricular preload reserve in dilated cardiomyopathy. Circulation. 1999;99:3009–3016.
   PubMed Web of Science ®Google Scholar
• Rakhit RD, Tousoulis D, Lefroy DC, Davies GJ. Differential nitric oxide synhase activity in ischemic and idiopathic dilated cardiomyopathy. Am J Cardiol. 1999;84:737–738.
   PubMed Web of Science ®Google Scholar
• Winlaw DS, Smythe GA, Keogh AM, Increased nitric oxide production in heart failure. Lancet. 1994;344:373–374.
   PubMed Web of Science ®Google Scholar
• Kalivendi SV, Kotamraju S, Zhao H, Doxorubicin induced apoptosis is associated with increased transcription of endothelial nitric oxide synthase. Effect of antiapoptotic antioxidants and calcium. J Biol Chem. 2001;276:47266–47276.
   PubMed Web of Science ®Google Scholar
• Weinstein DM, Mihm MJ, Bauer JA. Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice. J Pharmacol Exp Ther. 2000;294:396–401.
   PubMed Web of Science ®Google Scholar
• Fadillioglu E, Yılmaz HR, Erdoğan H, Söğüt S, The activities of tissue xanthine oxidase and adenosine deaminase and the levels of hydroxyproline and nitric oxide in rat heart subjected to doxorubicin: protective effect of erdosteine. Toxicology. 2003;191:153–158.
   PubMed Web of Science ®Google Scholar
• Sayed-Ahmed MM, Khattab MM, Gad MZ, Osman AM. Increased plasma endothelin and cardiac nitric oxide during doxorubicin-induced cardiomyopathy. Pharmacol Toxicol. 2001;89:140–144.
   PubMedGoogle Scholar
• Barnabe N, Marusak RA, Hasinoff BB. Prevention of doxorubicin-induced damage to rat heart myocytes by arginine analog nitric oxide synthase inhibitors and their enantiomers. Nitric Oxide. 2003;9;211–216.
   PubMed Web of Science ®Google Scholar
• Elli M, Soylemezoglu O, Erbas D, Plasma and urine nitric oxide levels in healthy Turkish children. Pediatr Nephrol. 2005;20:1605–1609.
   PubMed Web of Science ®Google Scholar
• Zhao G, Shen W, Zhang X, Loss of nitric oxide production in coronary circulation after the development of dilated cardiomyopathy: a specific defect in the neural regulation of coronary blood flow. Clin Exp Pharmacol Physiol. 1996;23:715–721.
   PubMed Web of Science ®Google Scholar
• Guerra J, De Jesus A, Santiago-Borrero P, Plasma nitric oxide levels used as an indicator of doxorubicin-induced cardiotoxicity in rats. Hematol J. 2005;5:584–588.
   PubMedGoogle Scholar
• Kremer LC, van Dalen EC, Offringa M, Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol. 2001;19:191–196.
   PubMed Web of Science ®Google Scholar
• Wojnowski L, Kulle B, Schirmer M, NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are assocaited with doxorubicin-induced cardiotoxicity. Circulation. 2005;112:3754–3762.
   PubMed Web of Science ®Google Scholar
• Farrell AJ, Blake DR. Nitric oxide. Ann Rheum. 1996;55:7–20.
   PubMed Web of Science ®Google Scholar
• Nathan C, Xie QW. Nitric oxide synthases: roles, tolls, and controls. Cell. 1994;78:915–918.
   PubMed Web of Science ®Google Scholar